Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ValbiotisXPAR:ALVAL -2.47%59 3-Year EPS without NRI Growth Rate is 26.90% as of Dec. 2025, which is 228% above its 10-year median of 8.20. GuruFocus rates XPAR:ALVAL with a GF Score™ of 59/100 and a GF Value™ of €1.18 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,537 Consumer Packaged Goods companies, Valbiotis ranks better than 72.09% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 26.90% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 6.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 11 years, the highest 3-Year average EPS without NRI Growth Rate of Valbiotis was 26.90% per year. The lowest was -91.20% per year. And the median was 8.20% per year.
Valbiotis (XPAR:ALVAL) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Valbiotis 3-Year EPS without NRI Growth Rate Related Terms
XPAR:ALVAL vs KHC, GIS: 3-Year EPS without NRI Growth Rate Comparison
For the Packaged Foods subindustry, Valbiotis's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valbiotis 3-Year EPS without NRI Growth Rate vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Valbiotis's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Valbiotis's 3-Year EPS without NRI Growth Rate falls into.
Valbiotis 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 26.90% mean?
Valbiotis (XPAR:ALVAL) has a 3-Year EPS without NRI Growth Rate of 26.90% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Valbiotis and its competitors. This is 228% above median its historical median of 8.20. According to the industry distribution chart, Valbiotis ranks #429 out of 1537 companies in the Consumer Packaged Goods industry, placing it in the top 27.9%.
Is Valbiotis' 3-Year EPS without NRI Growth Rate too high?
Valbiotis' current 3-Year EPS without NRI Growth Rate of 26.90% is 228% above median its 10-year median of 8.20. The Consumer Packaged Goods industry median 3-Year EPS without NRI Growth Rate is 7.40. Valbiotis' value of 26.90% is 263.5% above this industry median. Based on the distribution chart, Valbiotis ranks #429 out of 1537 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, Valbiotis has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valbiotis' 3-Year EPS without NRI Growth Rate compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Valbiotis ranks #429 out of 1537 companies for 3-Year EPS without NRI Growth Rate. This puts Valbiotis in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 7.40. Valbiotis' value of 26.90% is 263.5% above this benchmark. While the company's 10-year median is 8.20 vs. the industry median of 7.40, Valbiotis has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Consumer Packaged Goods company?
The median 3-Year EPS without NRI Growth Rate among Consumer Packaged Goods companies is 7.40, based on 1,537 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valbiotis's current 3-Year EPS without NRI Growth Rate of 26.90% is 263.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Valbiotis and its competitors. For the Consumer Packaged Goods industry, the median 3-Year EPS without NRI Growth Rate is 7.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valbiotis's current 3-Year EPS without NRI Growth Rate is 26.90%, which is 228% above median its own 10-year median of 8.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valbiotis stock overvalued right now?
Based on GuruFocus' analysis, Valbiotis (XPAR:ALVAL) is currently considered Possible Value Trap. The stock's GF Value™ is €1.18, compared to a current price of €0.75 — trading 36.4% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 26.90%, which is 228% above median its 10-year median of 8.20 and 263.5% above the Consumer Packaged Goods industry median of 7.40. Valbiotis' overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Valbiotis (XPAR:ALVAL), the current 3-Year EPS without NRI Growth Rate is 26.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valbiotis (XPAR:ALVAL) Overvalued in 2026?
Based on GuruFocus' analysis, Valbiotis stock appears to be undervalued.
The current stock price of €0.75 is trading 36.4% below its estimated GF Value™ of €1.18.
GuruFocus considers Valbiotis to be Possible Value Trap.
Key valuation signals for XPAR:ALVAL:
3-Year EPS without NRI Growth Rate: 26.90% (228% above median its 10-year median of 8.20)
GF Value™: €1.18 vs. price of €0.75 (36.4% below fair value)
Industry Position: 263.5% above the Consumer Packaged Goods median (#429 of 1537)
No single metric tells the full story. See the XPAR:ALVAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valbiotis SA is a research & development company. It is engaged in scientific innovation for preventing and combating metabolic diseases. Valbiotis has adopted an approach, aiming to revolutionize healthcare by developing a new class of Nutrition Health products designed to reduce the risk of metabolic diseases, based on a multi-target approach by the use of plant-based ingredients.
59GF Score
Get the complete analysis for XPAR:ALVAL
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALVAL has been successfully added to your 
